Japan's biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Now The Wall Street Journal is reviewing the biggest buyers and seeing who scored the juiciest gains, and who harvested bitter losses. Astellas Pharma, which acquired OSI Pharmaceuticals in 2010, comes out on top. Story